Valneva Starts COVID-19 Vaccine Production In Scotland
Initial Phase I/II Trial Data Expected In April
Executive Summary
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
You may also be interested in...
Coronavirus Update: New Funding For Valneva, Scotland Looks At Long COVID
France's Valneva raises new funds to progress its inactivated vaccine, while Scotland launches a new study into 'long COVID', Takeda reports positive interim results from a Japanese trial with Moderna's mRNA vaccine, a setback for GC's plasma therapy, and Celltrion begins exporting a therapeutic antibody.
Coronavirus Notebook: EMA Probes Janssen Vaccine Blood Clot Reports, UK Advises 12-Week Dosing Gap For Moderna
The AZ vaccine is now under EU scrutiny over capillary leak syndrome, while Valneva has reported positive results with its product. The global COVAX initiative has delivered more than 38 million doses of vaccines to over a hundred countries.
Coronavirus Update: Another Vaccine Disappointment For GSK
After suffering a setback in its joint venture with Sanofi, GlaxoSmithKline has been dropped by another vaccine partner, Clover, as it looks for the best adjuvant for its COVID-19 candidate.